Millennium Management LLC Buys Shares of 33,280 Cytosorbents Co. (NASDAQ:CTSO)

Millennium Management LLC purchased a new position in shares of Cytosorbents Co. (NASDAQ:CTSO) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 33,280 shares of the medical research company’s stock, valued at approximately $30,000. Millennium Management LLC owned approximately 0.06% of Cytosorbents as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also made changes to their positions in CTSO. Renaissance Technologies LLC increased its stake in Cytosorbents by 10.6% during the 4th quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company’s stock worth $80,000 after buying an additional 8,400 shares during the period. Northern Trust Corp boosted its position in Cytosorbents by 22.3% in the 4th quarter. Northern Trust Corp now owns 91,560 shares of the medical research company’s stock valued at $83,000 after buying an additional 16,701 shares during the period. Raymond James Financial Inc. acquired a new position in shares of Cytosorbents in the fourth quarter worth $99,000. Skylands Capital LLC increased its position in shares of Cytosorbents by 1.0% during the fourth quarter. Skylands Capital LLC now owns 2,781,622 shares of the medical research company’s stock worth $2,531,000 after acquiring an additional 26,195 shares during the period. Finally, Avenir Corp increased its position in shares of Cytosorbents by 4.0% during the fourth quarter. Avenir Corp now owns 3,093,946 shares of the medical research company’s stock worth $2,815,000 after acquiring an additional 118,387 shares during the period. Institutional investors and hedge funds own 32.87% of the company’s stock.

Cytosorbents Price Performance

Shares of CTSO opened at $1.09 on Friday. The firm has a market capitalization of $68.24 million, a price-to-earnings ratio of -3.03 and a beta of 1.05. The firm’s fifty day simple moving average is $0.96 and its 200-day simple moving average is $0.99. Cytosorbents Co. has a twelve month low of $0.70 and a twelve month high of $1.61. The company has a current ratio of 1.97, a quick ratio of 1.58 and a debt-to-equity ratio of 1.06.

Cytosorbents (NASDAQ:CTSO) last posted its earnings results on Wednesday, May 14th. The medical research company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.02. The firm had revenue of $8.73 million for the quarter, compared to analyst estimates of $9.01 million. Cytosorbents had a negative return on equity of 118.54% and a negative net margin of 49.47%. Equities analysts forecast that Cytosorbents Co. will post -0.3 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently issued reports on CTSO shares. HC Wainwright reiterated a “neutral” rating and issued a $1.00 target price on shares of Cytosorbents in a report on Thursday, May 15th. Wall Street Zen initiated coverage on Cytosorbents in a research note on Wednesday, May 21st. They issued a “hold” rating for the company. Finally, D. Boral Capital reissued a “buy” rating and set a $10.00 price objective on shares of Cytosorbents in a research report on Thursday, May 15th.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.